fbpx

Locoregional Stomach Cancer

Gastric Adenocarcinoma

Male, 61

Patient Internal ID: 21798324

ICD-10 code

C16.8 Malignant Neoplasm of Overlapping Sites of Stomach

Diagnosis (Incl. Metastases/Stage) and Year

2015
In 2019-03 recurrence of Gastric Adenocarcinoma cTXN3bM1 G2-3 stage IV, HER2 (-). Metastases in the Abdomen and Left Lung.

Previous Treatment

Surgery (Gastrectomy), Surgery (Resection of the Esophagus and Small Bowel), Chemotherapy (Cisplatin and 5-Fluorouracil), Immunotherapy (Ramucirumab) and Chemotherapy (Paclitaxel), Chemotherapy (FOLFIRI scheme).

Prognosis and Survival Expectation

The prognosis remains poor, the median survival for patients with Metastatic Gastric Cancer reported ±14 months.

Treatment Provided

Allogeneic CIK (5 doses) over a period of 5 months.

Patient Survival/Condition and Year
Date of Review: 01/12/2023

The patient has survived for 19 months since the recurrence of the disease. It can be concluded that the addition of Immunotherapy, alongside Surgery and Chemotherapy, has extended patient survival by an estimate of around 5 months.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.